2019
DOI: 10.3389/fphar.2019.00897
|View full text |Cite
|
Sign up to set email alerts
|

Efficacy and Safety of Multiple Dosages of Fostamatinib in Adult Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis

Abstract: Background: Rheumatoid arthritis is a type of systemic and complex autoimmune other disease characterized by chronic joint inflammation. Spleen tyrosine kinase (Syk) inhibitors are regarded as an effective alternative to existing drugs for the treatment of this disease. However, studies evaluating fostamatinib, a new Syk inhibitor, are either invalid or insufficient. Through a systematic review and meta-analysis, we evaluated the efficacy and safety of fostamatinib at different dosages in rheumatoid… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
26
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
6
2
1

Relationship

0
9

Authors

Journals

citations
Cited by 33 publications
(26 citation statements)
references
References 26 publications
0
26
0
Order By: Relevance
“…To date, many clinical trials on R788 have been completed and some have already evaluated its safety and efficacy for the RA treatment. The trials denoted that fostamatinib is an effective therapeutic medicine administered to patients with over 24 weeks [82]. Our experiments showed a central role of Syk kinase in the T-cell response to redox stress indicating it has a key role upstream of the Tyr phosphorylation cascade.…”
Section: Discussionmentioning
confidence: 63%
“…To date, many clinical trials on R788 have been completed and some have already evaluated its safety and efficacy for the RA treatment. The trials denoted that fostamatinib is an effective therapeutic medicine administered to patients with over 24 weeks [82]. Our experiments showed a central role of Syk kinase in the T-cell response to redox stress indicating it has a key role upstream of the Tyr phosphorylation cascade.…”
Section: Discussionmentioning
confidence: 63%
“…The drug was proposed on its action on AAK1 which is a regulator of endocytosis, although how AAK1 was prioritized as target was not described in the study. Fostamatinib, which we prioritized in this study, also inhibits JAK1, JAK2 and AAK1 48 based on curations from DrugBank and was shown to be effective for RA 43 . Of note, two other JAK-STAT signaling inhibitors were recommended by Stebbing et al 45 , while in our analysis JAK-STAT signaling is among the top 10 pathways enriched for top proteins linked to ACE2 expression.…”
Section: On Ace2 Expression and Exploring Drug Candidatesmentioning
confidence: 99%
“…This drug has been approved for treating Immune Thrombocytopenic Purpura (ITP), and is a spleen tyrosine kinase inhibitor 42 . There has been trials on rheumatoid arthritis (RA) 43 and IgA nephropathy as well 42 .…”
Section: On Ace2 Expression and Exploring Drug Candidatesmentioning
confidence: 99%
“…Anomalous regulation of this kinase could lead to different allergic disorders and antibody-mediated autoimmune diseases. Thus, Syk may serve as a therapeutically relevant target for rheumatoid arthritis, asthma, psoriasis, and allergic rhinitis [8][9][10]. It has been believed for years that Syk function is solely linked to hematopoietic cell signalling.…”
Section: Introductionmentioning
confidence: 99%